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Key questions
What is already known about this subject?
 ► Two LMNA genotype–phenotype cardiac correlations 
are currently reported: that cardiac involvement in 
multisystem laminopathies prevails with mutations 
upstream of the nuclear localisation signal (NLS), 
and that worse outcomes occur with non-missense 
(compared with missense) mutations.
What does this study add?
 ► More adverse phenotype was associated with mu-
tation location upstream of the NLS but not with 
non-missense mutations, although an association 
with non-missense mutations was identified in a 
subcluster with malignant ventricular arrhythmia.
How might this impact on clinical practice?
 ► Cardiac patients with an LMNA mutation locat-
ed upstream versus downstream of the NLS may 
have a more adverse cardiac phenotype, and some 
missense mutations can be as harmful as non-mis-
sense ones.
AbstrAct
Objective Two LMNA genotype–phenotype cardiac 
correlations are reported: first, that cardiac involvement 
in multisystem laminopathies prevails with mutations 
upstream of the nuclear localisation signal (NLS); second, 
that worse outcomes occur with non-missense (compared 
with missense) mutations. We tested whether LMNA 
mutation DNA location and mutation subtype can predict 
phenotype severity in patients with lamin heart disease.
Methods We used a semantic workflow platform and 
manual electronic literature search to identify published 
LMNA mutations with cardiac-predominant phenotype. 
Hierarchical cluster analysis (HCA) assembled lamin heart 
disease into classes based on phenotype severity. 176 
reported causative mutations were classified and any 
relationships to mutation location/subtype assessed by 
contingency analysis.
Results More adverse phenotype was associated with 
mutation location upstream of the NLS (p=0.014, OR 2.38, 
95% CI 1.19 to 4.80) but not with non-missense mutations 
(p=0.337, OR 1.36, 95% CI 0.72 to 2.57), although an 
association with non-missense mutations was identified 
in a subcluster with malignant ventricular arrhythmia 
(p=0.005, OR 2.64, 95% CI 0.76 to 9.21). HCA limited to 
the 65 mutations described on ClinVar as pathogenic/likely 
pathogenic showed similar findings (upstream of NLS, 
p=0.030, OR 4.78, 95% CI 1.28 to 17.83; non-missense, 
p=0.121, OR 2.64, 95% CI 0.76 to 9.21) as did analysis 
limited to pathogenic/likely pathogenic variants according 
to the American College of Medical Genetics and Genomics 
standards.
Conclusion Cardiac patients with an LMNA mutation 
located upstream versus downstream of the NLS have 
a more adverse cardiac phenotype, and some missense 
mutations can be as harmful as non-missense ones.
IntROduCtIOn
Lamins A and C are nuclear envelope proteins 
encoded by the LMNA gene (1q22). They 
are implicated in DNA replication, cell cycle 
regulation, chromatin organisation, differ-
entiation maintenance, nuclear stability, 
pore positioning, gene expression and signal 
transduction. LMNA mutations cause lamin-
opathies, a spectrum of multisystem diseases, 
including some types of muscular dystrophy, 
lipodystrophy and acrogeria syndromes.1 
They also cause lamin heart disease,2 which 
accounts for up to 10% of dilated cardiomyo-
pathies (DCM).3 Although there is significant 
pleiotropy of phenotypic expression in lamin 
heart disease,2 4 broadly it causes a malignant 
type of DCM with heart failure characterised 
by ventricular arrhythmias (VAs), cardiac 
conduction system disease (CCD) and an 
untreated sudden cardiac death (SCD) rate 
as high as 46%.5
Being intermediate filament proteins, 
lamins A and C have three domains: a short 
globular N-terminal head, a central rod and 
a long globular C-terminal tail (figure 1). 
Between the rod and the tail lies a critical 
sequence—the nuclear localisation signal 
(NLS)—responsible for nuclear residency.6 
Previous work has suggested that LMNA 
mutation position relative to the NLS 
predicts organ system involvement, with 
cardiac involvement prevailing with upstream 
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Figure 1 Three-dimensional model of wild-type lamin A. The LMNA gene uses an alternative 5’ splice site in intron 10 to 
generate four type A proteins: lamin A (major isoform, represented here, a.a. 664 protein with a molecular weight of 70 kDa), 
AΔ10 (minor isoform, missing exon 10), C (known as C1, a.a. 572) and C2 (only in germ cells). Each lamin protein has a tripartite 
domain organisation: short globular head, central α-helical rod and large immunoglobulin-like globular tail. Exons 7–9 code for 
tail domain sequences common to both lamins A and C. Highlighted in the model (red discontinuous box) are the five residues 
comprising the NLS sequence in exon 7 (a.a. 417–422) explaining its relationship to the other domains. The theoretical three-
dimensional model was assembled using lamin A major isoform (UniProtKB—P02545) primary amino acid sequence data in 
FASTA format submitted to the Protein Homology/analogY Recognition Engine V.2.0 workspace26 (Phyre2) as an intensive job 
type. a.a., amino acid; NLS, nuclear localisation signal.
mutations (ie, towards the N-terminal side).7 8 Three addi-
tional studies9–11 suggested worse outcomes in cardiac 
patients with non-missense as opposed to missense muta-
tions. The latter genotype–phenotype relationship led 
the current European guidelines to treat non-missense 
mutations as one of four risk factors for SCD in a patient 
with DCM with an LMNA mutation (class IIa, level of 
evidence B12 for primary prevention with an implant-
able cardioverter defibrillator). The four risk factors are 
non-sustained ventricular tachycardia, left ventricular 
ejection fraction <45%, male gender and non-missense 
mutations.
Since these studies, many more mutations have been 
reported in the literature. Accordingly, we sought to 
systematically study whether LMNA mutation DNA loca-
tion and subtype predict cardiac phenotype severity in 
patients with lamin heart disease.
MetHOds
data collection
An up-to-date list of LMNA mutations reported to cause 
cardiac-predominant disease (online supplementary 
table 1) was assembled from a semantic search using a 
workflow developed inhouse that implemented a Simple 
Object Access Protocol-based service to retrieve publica-
tions in Europe PubMed Central via the Taverna Work-
bench (V.2.5.0).13 This system preserves the exact input, 
key intermediate, final output and relevant external data 
of the search, and securely captures the code, computa-
tional configurations, parameters and their provenance. 
The Taverna search was combined with a manual litera-
ture search of PubMed, MEDLINE (Ovid) and EMBASE 
(Ovid) for publications on LMNA-related DCM/SCD 
spanning 1999 until February 2018 (details in online 
supplementary methods). Additionally, we searched the 
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National Center for Biotechnology Information Refer-
ence Sequences database14 (last accessed 30 January 
2018). These data were manually cross-checked with the 
Universal Mutation Database-LMNA mutation database 
at www. umd. be/ LMNA.
The nomenclature found in online supplementary 
table 1 is provided according to the Human Genome Vari-
ation Society using the reference sequence LMNA lamin 
A (NM_170707.3), except in cases indicated, for which 
the original publication used the reference sequence 
for the lamin C transcript (NM_005572.3). Assertions of 
clinical significance per mutation were sought from the 
ClinVar archive15 and are reproduced in online supple-
mentary table 1. Additionally, sequence variants were 
classified according to the American College of Medical 
Genetics and Genomics (ACMG) standards (www. acmg. 
net),16 17 and compared with entries in international 
databases, that is, The Human Gene Mutation Database18 
(http://www. hgmd. cf. ac. uk). Each reported mutation 
was examined by the following in silico predictive algo-
rithms: MutationTaster, PolyPhen-2, SIFT, PROVEAN 
and Condel (see online supplementary methods).
Mutation subtype was classified as non-missense (ins-
del/truncating or mutations affecting splicing) or 
missense (single nucleotide substitutions) as previously 
described10 and as alluded to in the European guideline. 
We also separately explored a refined classification of 
mutation subtype based on predicted molecular conse-
quences, thus aggregating missense | inframe inser-
tion/deletion (termed missense/inframe ins/del) into 
one group and frameshift | nonsense | complex dele-
tion | abnormal splicing mutations into another group, 
expected to have more adverse molecular consequences.
Mutation location was classified as upstream or down-
stream of the NLS with amino acid (a.a.) 417 as cut-off. 
For mutation location we also separately considered 
whether they occurred in the tail domain or upstream of 
the tail (a.a. 389 as cut-off, figure 1).
Phenotypic information per mutation was collected 
from the published literature to permit a MOGE(S) 
nosology classification.19 The MOGE(S) assigned to 
each mutation in online supplementary table 1 aggre-
gates all the phenotypic traits of interest in index cases 
as well as family members bearing that particular muta-
tion, from within the published literature. MOGE(S) is a 
five-letter phenotype–genotype standardised scheme for 
classifying cardiomyopathy endorsed by the World Heart 
Federation, similar to the tumour, node, metastases clas-
sification used in oncology. Its advantage is its ability to 
describe asymptomatic carriage, early disease forms and 
overlapping phenotypes. We scored for supraventricular 
arrhythmia; CCD (any degree of atrioventricular block 
as described in the original MOGE(S) scheme19); high 
creatine phosphokinase; juvenile onset (defined as age 
of first presentation <25 years); multisystem involvement 
(defined as any additional skeletal muscle, nervous, lipid, 
endocrine system manifestations); VA (defined as any type 
of non-life-threatening VA including ventricular ectopy); 
malignant ventricular arrhythmia ((MVA), defined as 
the potentially life-threatening VA, SCD, resuscitation or 
appropriate defibrillator therapy); and advanced heart 
failure ((aHF), defined as heart transplantation, death 
from end-stage heart failure or New York Heart Asso-
ciation functional classes III/IV). Although our study 
focused primarily on LMNA gene mutation carriers 
expressing a cardiac-predominant phenotype, some 
reported cases did secondarily have multisystem features, 
which is why we provisioned to score for multisystem 
involvement within the MOGE(S) as outlined above. 
Each subphenotypic attribute was scored as present (1)/
absent (0), except for MVA and aHF which were scored as 
present (2)/absent (0) in proportion with their greater 
clinical importance. We provisioned for 0–0 match to be 
a ground of similarity across all categories.
To explore the prevalence of identified LMNA gene 
mutations in the general population, we mined data on 
the Genome Aggregation Database (gnomAD, accessed 
19 December 2017, see online supplementary mate-
rial 2), which includes 123 136 exome sequences and 
15 496 whole-genome sequences from unrelated indi-
viduals20 (http:// gnomad. broadinstitute. org/ gene/ 
ENSG00000160789). For each variant identified the 
allele frequency was recorded.
statistical analyses
Unsupervised hierarchical cluster analysis (HCA) 
of the LMNA mutations with published and avail-
able phenotypic data was performed in R21 (packages 
‘ggdendro’, ‘dendextend’). HCA segregated mutation 
carriers with similar multidimensional phenotypes into 
related regions of a dendrogram using a Euclidian 
distance metric and Ward’s minimum variance method 
that minimises the total within-cluster variance. At each 
step the pair of clusters with minimum between-cluster 
distance was merged. To demonstrate that identified 
clusters did not arise by chance (clustering noise or 
sampling error), we assessed the cophenetic correlation 
between each clustering result, using a total of seven 
possible cluster algorithms. We compared clustering 
solutions when cut to k=4 clusters, using the Fowl-
kes-Mallows Index (giving a value of 1 when the two 
clusters conformed, and 0 when they did not). We used 
the package ‘pvclust’ to compute approximately unbi-
ased p values for all clusters contained in the clustering 
of original data by multiscale bootstrap resampling.
We used a 2×2 contingency analysis (χ2 or Fisher’s 
exact test as appropriate) to assess the relationship 
between HCA phenotype severity class, and (1) LMNA 
mutation subtype (missense vs non-missense; and 
missense/inframe ins/del vs others) and (2) LMNA 
mutation location (relative to the NLS and relative to 
the tail).
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Figure 2 Mutational landscape in lamin heart disease. A Circos of mutation subtype in cDNA order along the LMNA gene. 
Each mutation is described in online supplementary table 1. Exon boundaries are demarcated by sector lines (exon 12 only 
holds one mutation and the sector is not resolvable). From outside to in: gene mutation variant (text colours indicate mutation 
type; key, top left), then LMNA cDNA location track. The outermost track is colour-coded to match structurally and functionally 
important domains of the lamin protein (key, top right). The position of the NLS (red spoke) relative to the conserved IF-tail is 
also indicated. To date no cardiac disease-causing LMNA mutation has been reported affecting the NLS (red spoke), the Ser 
625 potential phosphorylation site (bright green spoke) or the lamin A specific –CaaX motif (a.a. 661–664, bright blue spoke). 
Circos was constructed in R (package ‘Circlize’). IF, intermediate filament. Other abbreviations as in figure 1.
Results
Reported LMNA mutations
A total of 199 cardiac-predominant LMNA mutations were 
identified, of which 109 (54.8%) were missense. Consid-
ering the refined classification, 111 mutations were in the 
missense/inframe ins/del group (63%). One hundred 
and seventy-six mutations (88%; figure 2) included suffi-
cient published phenotypic information for a MOGE(S) 
classification to be used in the subsequent HCA. Of these, 
65 carried a pathogenic/likely pathogenic assertion of 
clinical significance in ClinVar, while the remainder had 
conflicting interpretation of pathogencity or were of 
uncertain significance. Fifty-two (26%) published muta-
tions were absent from ClinVar, and 45 (23%) although 
listed on ClinVar had no assertion of clinical significance 
provided. Of the 176 mutations used in the HCA, 145 
carried a pathogenic/likely pathogenic assertion of clin-
ical significance according to the ACMG standards.
Possibly as a result of lethality, we found that no cardiac 
disease-causing LMNA mutation has been reported 
affecting the (1) NLS (a.a. 417–422); (2) Ser 625 poten-
tial phosphorylation site; or (3) the lamin A specific –
CaaX motif (a.a. 661–664; see figure 2), while only one 
mutation has been detected in the unique lamin C C-ter-
minal sequence (VSGSRR, a.a. 566_572, NM_005572.3). 
Collectively these make up 2.9% of the entire lamin 
cDNA sequence.
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Phenotypic clustering
Unsupervised HCA consistently identified two main 
phenotypic groups (figures 3 and 4, and online supple-
mentary table 2): 61 and 115 mutations in the clusters 
with less and more adverse phenotypes, respectively. 
Computational analysis suggested that the different 
clustering algorithms gave similar segregation results 
even when cut using the Fowlkes-Mallows Index (online 
supplementary table 3). HCA also consistently identified 
a smaller phenotypic subcluster (29 mutations; figure 3) 
characterised by MVA in the absence of aHF.
Association between genotype and phenotype
There was an association between more adverse cardiac 
phenotype and LMNA DNA location upstream of the NLS 
(p=0.014, OR 2.38, 95% CI 1.19 to 4.80). HCA repeated 
for mutations relative to the tail domain similarly showed 
an association of more adverse cardiac phenotype with 
mutations upstream of the tail (p=0.013, OR 2.34, 95% CI 
1.18 to 4.60) compared with those in the tail.
There was no association between non-missense muta-
tion and more adverse cardiac phenotype (p=0.337, OR 
1.36, 95% CI 0.72 to 2.57) except in the MVA subcluster, 
where non-missense mutations prevailed (p=0.005, OR 
2.64, 95% CI 0.76 to 9.21). Repeating the HCA limited 
to the 65 LMNA mutations with pathogenic/likely patho-
genic assertions listed in ClinVar showed a similar asso-
ciation between more adverse cardiac phenotype and 
mutation location upstream of the NLS (p=0.030, OR 
4.78, 95% CI 1.28 to 17.83) and upstream of the tail 
(p=0.042, OR 3.89, 95% CI 1.10 to 13.81), but not with 
non-missense mutation subtype (p=0.121, OR 2.64, 95% 
CI 0.76 to 9.21), except again in the MVA subcluster (11 
mutations), where non-missense mutations prevailed 
(p=0.043, OR 4.16, 95% CI 1.07 to 16.20). Repeating 
the HCA limited to the 145 LMNA mutations with 
pathogenic/likely pathogenic assertions according to 
the ACMG standards confirmed an association between 
more adverse cardiac phenotype and mutation location 
upstream of the NLS (p=0.012, OR 2.76, 95% CI 1.22 to 
6.22) and upstream of the tail (p=0.028, OR 2.42, 95% 
CI 1.09 to 5.40), but not with non-missense mutation 
subtype (p=0.841, OR 1.08, 95% CI 0.52 to 2.24) except in 
the MVA subcluster (26 mutations), where non-missense 
mutations prevailed (p=0.032, OR 2.54, 95% CI 1.06 to 
6.07). Repeating the HCA considering the 176 mutations 
reclassified into missense/inframe ins/del versus others 
showed no association between mutation subtype and 
cardiac phenotype severity (p=0.406, OR 1.32, 95% CI 
0.69 to 2.53).
Frequency of LMNA mutations in a general population 
database
Twenty-six of the 199 LMNA unique mutations presented 
in online supplementary table 1 (not counting the intronic 
variant, c.1158–44C>T—see below) were identified in 
gnomAD, amounting to a total of 704 LMNA mutations 
across the 138 632 gnomAD participants (0.51%). Eleven 
of these 26 mutations (42%) carried a pathogenic/likely 
pathogenic assertion on ClinVar. The majority (82%) of 
LMNA mutations identified in gnomAD were missense 
and located downstream of the NLS (83%). We did not 
count the intronic c.1158–44C>T mutation as it has only 
been described in one paper (online supplementary 
table 1), was identified in gnomAD at relatively high allele 
frequency (0.01069%) and is missing functional data.
dIsCussIOn
Lamin heart disease accounts for 10% of DCM and is 
more malignant than typical DCM. By mining published 
mutations, and correlating mutation type and location 
with phenotype using a MOGE(S) scheme, we identified 
199 published cardiac LMNA mutations. Some of these 
may be surprisingly common in the general population 
as we identified 704 in the 138 632 general population 
participants making up the gnomAD database.
Previously LMNA mutations upstream of the NLS 
(exons 1–6) were shown to have more cardiac organ 
involvement compared with other systems.7 Here we show 
for the first time in patients with lamin heart disease that 
such mutations have a more malignant cardiac pheno-
type compared with downstream mutations. Further-
more, it is not just mutations upstream of the NLS, but 
anywhere upstream of the tail (of the 176 unique muta-
tions, 75% are upstream of the NLS; 72% are upstream 
of the tail). In support of this, LMNA mutations identi-
fied in the apparently healthy gnomAD population were 
rarely upstream of the NLS—eight times more likely to be 
located downstream (83 vs 621 allele counts). HCA data 
suggest that mutations upstream of the NLS, irrespective 
of mutation subtype, may be having a greater impact on 
protein structure and function relevant to the heart, and 
consequently on phenotypic expression, compared with 
mutations in and around the tail. One reason for this is 
that the region upstream of the NLS harbours the highly 
conserved rod domain, which is key to lamin protein 
assembly into mechanostructurally robust dimers (and 
then protofilaments, filament bundles, tangles and finally 
paracrystalline arrays). Another hypothesis is that while 
upstream mutations will invariably corrupt both isoforms, 
the lamin C isoform may be unscathed with more down-
stream mutations, thus potentially compensating for 
the mutant/deficient lamin A, mitigating phenotypic 
expression. The HCA data also show that while non-mis-
sense mutation subtype alone was insufficient to explain 
worse phenotype overall, it associated with MVA, as per 
the published literature and existing guideline. We 
go on to show that non-missense mutations are rare in 
the gnomAD population (12%) when compared with 
missense ones. Indeed, missense LMNA mutations distal 
to the NLS were the most common variants to be encoun-
tered in the gnomAD database search.
This work is the first time the MOGE(S) system was 
used to systematically classify mutation-specific morpho-
functional subphenotypes across the published LMNA 
Open Heart
6 Captur G, et al. Open Heart 2018;5:e000915. doi:10.1136/openhrt-2018-000915
Figure 3 Hierarchical clustering of subphenotypic attributes in lamin heart disease. A dendrogram (A) was generated by 
unsupervised hierarchical clustering of 176 reported mutations. The horizontal limbs of the dendrogram represents the distance 
or dissimilarity between clusters. The vertical axis represents the objects and clusters. Fusion of two clusters is represented 
by a horizontal line splitting into two horizontal lines. The horizontal position of the split, shown by the short vertical line, 
summarises the dissimilarity between the two clusters. Looking at this dendrogram, one can see four clusters as four branches 
that occur at about the same horizontal distance. The phenotypic clusters were identified according to phenotype severity. 
The discontinuous green box (purple dendrogram at the top) highlights the mildest phenotype cluster, while the discontinuous 
red box (burgundy dendrogram at the bottom) highlights a cluster with MVA but not aHF that is enriched with non-missense 
mutations. AU p values per cluster are shown in red. Heat map key (B) denotes the relative intensities of each subphenotypic 
attribute scored in a sequential green colour gradient (extending over three units: 0, 1, 2). Values ≥95% are strongly supported 
by data. Coloured ribbons (C–E) summarise mutation-specific properties: (C) non-missense in green, missense in grey; (D) 
DNA location upstream of NLS in red, downstream in tan; (E) DNA location upstream of the tail in blue, downstream in tan. 
The subphenotype per mutation is presented in the form of a heatmap (F). The mutation list is provided on the far right (G). 
aHF, advanced heart failure defined as heart transplantation, death from end-stage heart failure or New York Heart Association 
functional class III/IV; AU, approximately unbiased; CCD, cardiac conduction system disease; CK, elevated creatine 
phosphokinase; juvenile, age of phenotypic penetrance <25 or ≥25 years, considering the earliest reported age of phenotypic 
expression in the proband or affected family members; M-system, multisystem involvement; MVA, malignant ventricular 
arrhythmia defined as sudden cardiac death, resuscitation or appropriate defibrillator therapy; SA, supraventricular arrhythmia; 
VA, any type of documented ventricular arrhythmia including ventricular ectopy. Other abbreviations as in figure 1.
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Figure 4 Hierarchical clustering of subphenotypic attributes in lamin heart disease limited to the pathogenic/likely pathogenic 
variants listed in ClinVar (n=65). Four significant phenotypic clusters (A) were identified according to phenotype severity. The 
discontinuous green box (purple dendrogram at the top) highlights the mildest phenotype cluster, while the discontinuous 
red box (burgundy dendrogram at the bottom) highlights a cluster with MVA but not aHF that is enriched with non-missense 
mutations. AU p values are shown in red. Heat map key (B) denotes the relative intensities of each subphenotypic attribute 
scored in a green sequential colour gradient (extending over three units: 0, 1, 2). Coloured ribbons (C, D) summarise mutation-
specific properties: (C) non-missense in green, missense in grey; (D) DNA location upstream of NLS in red, downstream in tan. 
The subphenotype per mutation is presented in the form of a heatmap (E). The mutation list is provided on the far right (F). 
Abbreviations as in figure 1 and 3.
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Total number of 
unique mutations 
studied, NM|M Associated endpoint
Pasotti et al9 Retrospective, one-
centre
94, 35 | 59 23, 9 | 14  ► NM not associated with all events at UA.
 ► Splice site mutation associated with SCD at UA only.




269, 122 | 147 74, 36 | 38  ► NM not associated with MVA at UA.
 ► Considering date of birth until time of MVA (lifetime 
risk) NM shows independent association.
Kumar et al28 Retrospective, five-
centre
120, 51 | 69 55, 19 | 35 (+1 double M 
and NM)
 ► NM independently associated with sustained VA and 
death.
Current HCA Retrospective, / / 176, 75 | 101  ► NM not associated with phenotype severity by HCA.
All studies regard exonic single nucleotide substitutions as missense mutations, and all others as non-missense.
*Mutation list for study participants was provided in a later separate publication (ref 27).
HCA, hierarchal cluster analysis ; M, missense ; MVA, malignant ventricular arrhythmia; NM, non-missense; SCD, sudden cardiac death; UA, 
univariate analysis; VA, ventricular arrhythmia.
literature. We chose to employ hierarchical cluster 
agglomeration as this method is well suited for the inter-
rogation of nominal data such as ours, by permitting a 
great many distance functions invented for nominal 
data, and theoretically more sound in this context than 
simply Euclidean distance. By combining a manual litera-
ture search with a transparent and reproducible22 search 
implemented through the Taverna workflow manage-
ment system, we assembled a more up-to-date list of muta-
tions that is sevenfold the number of mutations appraised 
by Pasotti et al,9 double that of van Rijsingen et al10 and 
triple that of Kumar et al11 (details provided in table 1). A 
significant number of LMNA mutations used in our anal-
ysis were not yet available to investigators listed in table 1 
(112 variants were published after 2008; 19 variants were 
published after 2013), and even now more novel muta-
tions continue to emerge.23
The vast majority of disease-causing LMNA mutations 
are known to be sequence-level alterations and predomi-
nantly missense. Frameshift, nonsense, abnormal splicing 
and intragenic deletions and duplications, capable 
of resulting in a loss-of-function (haploinsufficiency), 
would be expected to have greater clinical impact when 
compared with single nucleotide substitutions. Data from 
three retrospective studies suggested this9–11 (table 1), 
but it is possible that the effect of some non-missense 
mutations may have been over-represented on account 
of inter-relatedness and clustering effects. Furthermore, 
some reported associations were tenuous or only apparent 
after reanalysis for lifetime risk of MVA.10 Non-missense 
mutations are currently considered a risk factor for SCD 
in the European guidelines,12 and indeed we confirmed 
an association between non-missense mutations and 
MVA in one subcluster. However, implicit in the guide-
line approach is the consequent treatment of all missense 
mutations as comparatively ‘less adverse’. While some 
such literature examples certainly exist, like the mild and 
late-onset phenotype reported for missense mutation 
p.Arg331Gln,24 other LMNA missense mutations have 
unequivocally been linked to highly adverse phenotypes 
(eg, p.Arg190Trp and p.Glu161Lys,9 both missense and 
located upstream of the NLS). Emerging data therefore 
suggest there may be a spectrum of phenotypic severity 
stemming from missense mutations of the LMNA gene 
with different mechanisms. A number of missense muta-
tions are probably acting through a dominant negative 
pathway with adverse clinical consequences. For example 
in the case of the p.Ser143Pro missense mutation, the 
full length but aberrant lamin protein has been shown 
to accumulate, forming abnormal, round nucleoplasmic 
aggregates25 that would fit with a dominant negative 
effect. In keeping with this biological complexity, our 
HCA data suggest that the broad-based categorisation 
of mutations into ‘non-missense’ and ‘missense’ may be 
oversimplistic—yet as current guidelines suggest, there 
is a subset of patients with non-missense mutations at 
high risk of MVA; however, there are also a number of 
patients with missense mutations in the C-terminal exons 
of the LMNA gene expressing highly adverse phenotypes, 
which current guidelines may potentially misclassify if the 
four-variable SCD risk algorithm is applied, with conse-
quent deferral of life-saving defibrillator implantation.
Limitations of our work include the reliance on 
reported mutations and clinical details from the litera-
ture, and possibly therefore inconsistent and incomplete 
data sets from different centres. While the genetic data 
published may have been precise, the scope and quality 
of the phenotype data and clinical investigations may 
not have been rigorous and occasionally incomplete, 
explaining our inability to include 12% of the 199 orig-
inally identified. Here we have focused on LMNA muta-
tions with cardiac-predominant phenotype, as opposed 
to extending HCA to the much larger and broader multi-
system laminopathies. We used an overall cardiac severity 
score rather than focusing on one specific aspect such as 
SCD as some published cohort studies may have done. 
Through the ACMG classification of variants, we incorpo-
rate into the HCA at least some modelling of predicted 
9Captur G, et al. Open Heart 2018;5:e000915. doi:10.1136/openhrt-2018-000915
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structural disruption by specific mutations on the tertiary 
structure of lamin A/C; however, the downstream effects 
on interacting molecules have not been modelled. 
Although the more malignant phenotypes (MVA and 
aHF) are known to be age-dependent, their individual 
age dependency was not scrutinised here on account 
of the heterogeneity of reported data in the published 
literature. Juvenile onset was therefore systematically 
captured instead. Future work should seek to rigorously 
investigate the relationship between the more adverse 
cardiac phenotype and gender.
COnClusIOn
Lamin mutations upstream of the NLS or C-terminal tail 
domain associate with an overall more severe cardiac 
phenotype than those downstream, and some missense 
mutations can be as harmful as non-missense ones. Repli-
cation of findings in a larger prospective lamin heart 
disease cohort is needed to understand whether future 
cardiac guidelines should consider incorporating some 
of the more adverse missense mutations and mutation 
location (upstream of the NLS or C-terminal tail domain) 
for patient risk stratification.
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